+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P04389(RTN4 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The RTN4 antibody targets Reticulon-4 (RTN4), a protein encoded by the RTN4 gene, also known as Neurite Outgrowth Inhibitor (Nogo). RTN4 belongs to the reticulon family, which is characterized by conserved reticulon homology domains and involvement in endoplasmic reticulum (ER) membrane shaping. RTN4 exists in three major splice variants: Nogo-A, Nogo-B, and Nogo-C. Nogo-A, the longest isoform, is predominantly expressed in the central nervous system (CNS) and is known for its role in inhibiting axonal regeneration and plasticity via interactions with the Nogo-66 receptor (NgR1) and paired immunoglobulin-like receptor B (PirB). This inhibitory function has made RTN4 a key focus in studies on spinal cord injury and neurodegenerative diseases.

RTN4 antibodies are widely used in neuroscience research to investigate mechanisms of neural repair, myelin-associated inhibition, and CNS regeneration. They also play roles in studying non-neuronal processes, such as vascular remodeling (Nogo-B in endothelial cells) and apoptosis regulation. Commercial RTN4 antibodies are designed to distinguish specific isoforms or domains, enabling applications in Western blotting, immunohistochemistry, and flow cytometry. Beyond basic research, RTN4 antibodies have therapeutic potential, with preclinical studies exploring their use in neutralizing inhibitory signals to enhance recovery after neural damage.